We aim to improve people’s quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses experience it has gained from over a century in the business.
Co-leader of WP5, WP7, and WP8, Participant in WP1, WP2, WP4, WP6, and WP9.
I.R.I.S.
Institut de Recherches Internationales Servier (EFPIA member company)
I.R.I.S.
Institut de Recherches Internationales Servier, founded in 1954, is the first French independent pharmaceutical group. We are present in 140 countries, with more than 21 000 employees, including close to 3000 in R&D.
Co-leader of WP3, Participant in WP1, WP8, and WP9.
SARD
Sanofi-Aventis Research and Development (EFPIA member company)
SARD
Sanofi is a global healthcare leader focused on patients’ needs engaged in the research, development, manufacturing and marketing of innovative therapeutic solutions. Sanofi has core strengths in healthcare, with 7 growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Co-leader of WP4.
Lilly
Eli Lilly and Company (EFPIA member company)
Lilly
Since our founding by Col. Eli Lilly in 1876, we have been committed to discovering solutions to our world’s most pressing health problems. More than a century later, we remain true to our founding family’s vision and values – to create high quality medicines with integrity, excellence and respect for people. Across the globe, you will find Lilly employees working tirelessly to bring life-changing medicines to people who need them, offering support to patients and families living with serious illness, and giving back to their communities and the environment through countless acts of service. Our heritage and our values are the foundation of our mission to unite caring and discovery to make life better for people around the world..
Co-leader of WP2, Participant WP1, WP3, WP8.
Project Partners
BAYER
BAYER Pharma AG (EFPIA member company)
I.R.I.S.
Institut de Recherches Internationales Servier (EFPIA member company)
SARD
Sanofi-Aventis Research and Development (EFPIA member company)
This website reflects only the author’s views and neither IMI nor the European Commission are liable for any use that may be made of the information contained therein.
PRECISESADS receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115565], resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
